Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2021–2022

Annual recommendations on the use of influenza vaccine in Canada are developed by the NACI Influenza Working Group (IWG) for consideration by NACI. Recommendations are developed based on a review of a variety of issues, which can include: the burden of influenza illness and the target populations for vaccination; efficacy, effectiveness, immunogenicity, and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. In addition, PHAC has expanded the mandate of NACI to include the consideration of programmatic factors in developing their recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels. These programmatic factors include economics, ethics, equity, feasibility, and acceptability.

Données et ressources

Info additionnelle

Champ	Valeur
Source
Version
Producteur
Courriel de l'auteur
Mainteneur
Courriel du mainteneur
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French)	Chapitre sur la grippe du Guide canadien d’immunisation et Déclaration sur la vaccination antigrippale pour la saison 2021-2022
Update Frequency	unknown
Geographic Scope	[]
Criticality Level	[]
Sensitivity Level	unrestricted
Langue
Contact Person
Contact Email
Dictionnaire de données
Open Canada Date Published	2021-05-31 00:00:00
Open Canada Date Modified
Open Canada Subject	["health_and_safety"]
Open Canada Keywords	{"fr": ["vaccin", "grippe", "Comité", "consultatif", "national", "l’immunisation", "Une déclaration", "d'un comité consultatif", "DCC", "CCNI", "ARN", "Acide", "ribonucléique", "CDC", "Centers for Disease Control", "Prevention", "DIN", "Numéro", "d'identification", "médicament", "ECR", "Essai", "contrôlé", "randomisé", "ÉI", "Évènements", "indésirables", "ESSI", "EP", "Efficacité", "potentielle", "réelle", "Effet", "secondaire", "suivant", "GCI", "Guide", "canadien", "HAART", "HA", "Hémagglutinine", "Traitement", "antirétroviral", "hautement", "actif", "IC", "Intervalle", "confiance", "Ig", "Immunoglobuline", "IM", "Intramusculaire", "IMC", "Indice", "masse", "corporelle", "IMPACT", "Programme", "canadien", "surveillanc", "active", "de", "MGT", "Moyenne", "géométrique", "titres", "NA", "Neuraminidase", "OMS", "Organisation", "mondiale", "Santé", "PS", "Professionnel", "santé", "RMGT", "Rapport", "de la moyenne", "géométrique", "titres", "RRO", "Vaccin contre", "rougeole", "rubéole", "oreillons", "SCSESSI", "Système", "canadien", "surveillance", "SGB", "Syndrome", "Guillain-Barré", "SOR", "Syndrome", "oculo-respiratoire", "TNDN", "Troubles", "neurologiques", "développement", "neurologique", "TS", "Travailleur", "santé", "UFF", "Unité", "foyers", "fluorescents", "VII", "Vaccin", "inactivé", "contre", "l'influenza", "VII3", "Vaccin trivalent", "inactivé", "contreVII3-Adj", "Vaccin", "inactivé", "contre", "adjuvant", "VII3-SD", "Vaccin", "trivalent", "inactivé", "contre", "dose", "standard", "VII3-HD", "trivalent", "contre", "haute", "VII4", "quadrivalent", "VII4-SD", "VIH", "Virus", "immunodéficience", "humaine", "VRZ", "recombinant", "zona", "VVAI", "vivant", "atténué", "VVAI3", "atténué", "VVAI4"], "en": ["Influenza", "vaccine", "National", "Advisory", "Committee", "Immunization", "Adverse", "event", "AEFI", "CAEFISS", "Canadian", "Adverse", "Events", "Following", "Immunization", "Surveillance", "System", "CI", "Confidence", "interval", "CIG", "Canadian", "Guide", "DIN", "Drug", "Identification", "Number", "FFU", "Fluorescent", "focus", "units", "GBS", "Guillain-Barré", "syndrome", "GMT", "Geometric", "mean", "titre", "GMTR", "Geometric", "ratio", "HA", "Hemagglutinin", "HAART", "Highly", "active", "antiretroviral", "therapy", "HCW", "Health", "care", "worker", "HIV", "Human", "immunodeficiency", "virus", "Ig", "Immunoglobulin", "IIV", "Inactivated", "IIV3", "Trivalent", "inactivated", "IIV3-Adj", "Adjuvanted", "IIV3-HD", "High-dose", "trivalent inactivated", "IIV3-SD", "Standard-dose", "IIV4", "Quadrivalent", "inactivated", "IIV4-SD", "Standard-dose", "ILI", "Influenza-like", "illness", "IM", "Intramuscular", "Immunization", "Monitorin", "Program", "Active", "LAIV", "Live", "attenuated", "LAIV3", "Trivalent", "live", "attenuated", "LAIV4", "Quadrivalent", "MMR", "Measles", "mumps", "rubella", "NA", "Neuraminidase", "NACI ORS", "Oculorespiratory", "syndrome", "RCT", "Randomized", "controlled", "trial", "RNA", "Ribonucleic acid", "RZV", "Recombinant", "zoster", "vaccine", "SAE", "Serious", "adverse", "event", "VE", "Vaccine", "effectiveness", "WHO", "World Health", "Organization", "Advisory", "Committee", "Statement", "ACS", "IMPACT"]}
Open Canada Collection	publication
Principal Organization
Reference Data
Official Source